SLRN ACELYRIN INC

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that members of its management team will participate in fireside chats and 1x1 meetings at the following investor conferences:

Wells Fargo Healthcare Conference 2024

Date: Thursday, September 5, 2024

Location: Boston, MA

Fireside chat: 1:30 PM - 2:05 PM ET

Morgan Stanley 22nd Annual Global Healthcare Conference

Date: Friday, September 6, 2024

Location: New York, NY

Fireside chat: 11:30 AM - 12:05 PM ET

H.C. Wainwright 26th Annual Global Investment Conference

Date: Monday, September 9, 2024

Location: New York, NY

Fireside chat: 2:00 PM - 2:30 PM ET

Live webcasts of the fireside chats will be available on the Company’s website under . Replays of each webcast will be available on the Company’s website for 30 days following the event.

About ACELYRIN, INC.

ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN’s lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.

For more information about ACELYRIN, visit us at  or follow us on and .

Forward Looking Statements

Some statements in this press release are, or may be considered, forward-looking statements, including statements regarding ACELYRIN’s business plans and potential future benefits of our pipeline. While ACELYRIN, INC. considers any projections to be based on reasonable assumptions, these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated in such forward-looking statements.

ACELYRIN Contacts:

Tyler Marciniak

Vice President of Investor Relations and Corporate Affairs





EN
22/08/2024

Underlying

SLRNACELYRIN INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ACELYRIN INC

 PRESS RELEASE
Free
SLRN ACELYRIN INC

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Bi...

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company’s special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company’s merger agreement with Alumis Inc...

May 13, 2025 1 EN
 PRESS RELEASE
Free
SLRN ACELYRIN INC

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockh...

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has reco...

May 6, 2025 1 EN
 PRESS RELEASE
Free
SLRN ACELYRIN INC

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alum...

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that the proposed combination with Alumis Inc. (Nasdaq: ALMS) is the best path forward and the most value-maximizing outcome for a...

May 1, 2025 1 EN
 PRESS RELEASE
Free
SLRN ACELYRIN INC

Alumis and ACELYRIN Announce Amended Merger Agreement

Alumis and ACELYRIN Announce Amended Merger Agreement ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board proces...

April 21, 2025 1 EN
 PRESS RELEASE
Free
SLRN ACELYRIN INC

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (“Rights Plan”). The ACELYRIN Board and management team continue to engage with stockholde...

March 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch